ClinicalTrials.gg
CompletedNCT01126541Updated Sep 15, 2014Results posted

SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy

A Phase 3 interventional study of rituximab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 53 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-15.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
22nd of 63
224 · median 159
Started
2006
with 10 others
Phase 3
27 of 63
1 open now
Registered
28th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 22nd largest by enrollment, is one of 11 that started in 2006, is one of 27 in phase 3, and was the 28th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will compare the efficacy and safety of re-treatment with 2 doses of MabThera (rituximab) in patients with active rheumatoid arthritis (RA) who have previously experienced an inadequate response or intolerance to anti-tumor necrosis factor (anti-TNF) therapies etanercept, infliximab or adalimumab therapy. All patients will receive infusions of 1000 mg intravenous (IV) MabThera on Days 1 and 15; at Week 24 patients who have demonstrated a moderate or good response will be randomized to receive re-treatment with either 1 or 2 additional infusions of 1000 mg IV MabThera. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients >18 years of age
  • RA for >=6 months
  • Receiving outpatient treatment
  • Ongoing treatment with methotrexate for >=3 months, stable for >=1 month
  • Inadequate response or intolerance to etanercept, infliximab or adalimumab

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with MabThera
  • Concurrent treatment with any anti TNF-alfa therapy or biologic therapy
  • Previous treatment with any cell-depleting therapies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    A

    1000 mg IV rituximab

    Drug: rituximab

  • Experimental
    B

    2 x 1000 mg IV rituximab

    Drug: rituximab

Interventions

  • Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months

    Also known as: MabThera/Rituxan

06

What researchers measure

Primary outcomes

  1. Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 104

    DAS28-CRP was based on joint counts, overall participant assessment, and serum CRP levels (measured in milligrams per liter \[mg/L\]) at each visit. Joint counts included swollen joint count (SJC) and tender joint count (TJC). Total score range was 0 to 9.4; a higher score indicated more disease activity. DAS28-CRP less than or equal to (≤)3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and less than (\<)2.6 equals (=) remission. The AUC of all DAS28-CRP values between Day 1 and Week 104 (15 values of protocol visits) was calculated using the trapeze method (AUC between t1 and t2=(t2-t1)\*((DAS28-CRP at t1 + DAS28-CRP at t2)/2). The true visit dates were used to calculate the time between 2 DAS28-CRP evaluations. All the AUC were censored at Week 104 (linear extrapolation using the 2 last DAS28-CRP values (Weeks 96 and 104) to obtain the "true" DAS28-CRP value at the "true" Week 104).

    Time frame: Week 104

Secondary outcomes

  1. DAS28-CRP During the Initial Treatment

    Mean DAS28-CRP at Week 24 of the Initial Treatment study. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-CRP ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.

    Time frame: Days 1 and 15, and Weeks 6, 12, and 24

  2. DAS28-CRP and Changes From Baseline to Week 24 in DAS28-CRP by Retreatment Course

    DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.

    Time frame: Day 1, 24 weeks following each infusion up to 72 Weeks

  3. Percentage of Participants Achieving Clinical Remission (DAS28-CRP <2.6) or Low Disease Activity (DAS28-CRP ≤3.2)

    Percentage of participants with clinical remission and low disease activity as measured by DAS28-CRP for Arm A and Arm B at Week 24 of the Initial Treatment, at 24 weeks after first re-treatment, and at 24 weeks after second retreatment. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity and \<2.6 = remission.

    Time frame: Week 24 of the Initial Treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment

  4. DAS28-CRP AUC Weighted Time

    DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.

    Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104

  5. Time to Achieve DAS28-CRP Remission After the First Course

    DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.

    Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104

  6. Time to Achieve DAS28-CRP Remission After Retreatment

    DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.

    Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104

  7. Time to Achieve DAS28-CRP ≤3.2 After the First Course of Treatment

    DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.

    Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104

  8. Time to Achieve DAS28-CRP ≤3.2 After Retreatment

    DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.

    Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104

  9. Duration of DAS28-CRP Remission After the First Course of Treatment

    DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.

    Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104

  10. Duration of DAS28-CRP Remission After Retreatment

    DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.

    Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104

  11. Duration of DAS28-CRP ≤3.2 After the First Course of Treatment

    DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.

    Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104

  12. Duration of DAS28-CRP ≤3.2 After Retreatment

    DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.

    Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104

  13. Percentage of Participants Achieving American College of Rheumatology 20%, 50%, and 70% Improvement (ACR20/ACR50/ACR70)

    ACR20/50/70 response defined as ≥20%, 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%, 50%, or 70% improvement, respectively, in at least 3 of 5 remaining ACR core measures: Patient Global Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity (on a visual analog scale \[VAS\]); Health Assessment Questionnaire-Disability Index (HAQ-DI); and CRP.

    Time frame: Week 24 of the initial treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment

  14. Percentage of Participants Achieving a Response During Initial Treatment by European League Against Rheumatism (EULAR) Category

    DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline \>1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤ 5.1 or change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline \>0.6 and ≤ 1.2 with a DAS28 score of \>5.1.

    Time frame: Day 15, Weeks 6, 12, and 24

  15. Percentage of Participants Achieving a Response During Retreatment by EULAR Category

    DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline \>1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤ 5.1 or change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline \>0.6 and ≤ 1.2 with a DAS28 score of \>5.1.

    Time frame: Week 24, 24 weeks after 1st retreatment, 24 weeks after 2nd retreatment

  16. Percentage of Participants With Rheumatoid Factor (RF) at 24 Weeks After Treatment

    RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 international units per milliliter (IU/mL) is considered positive.

    Time frame: Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment

  17. Percentage of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at 24 Weeks After Treatment

    Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual's own proteins) that are frequently detected in the blood of rheumatoid arthritis participants. Anti-CCP antibodies value higher than 10 U/mL is considered positive.

    Time frame: Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment

  18. Physician's Global Assessment of Disease Activity

    The Physician's Global Assessment of disease activity is assessed on a 0 to 100 millimeter (mm) horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Physicians were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high disease activity).

    Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment

  19. Patient Global Assessment of Disease Activity

    The Patient's Global Assessment of Disease Activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).

    Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment

  20. Patient's Global Assessment of Pain

    The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).

    Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment

  21. Participant Assessment of Fatigue

    Participants were asked to rate their level of fatigue over the last 7 days on a 100-mm VAS. The left-hand extreme of the line equals 0 mm, and is described as "no fatigue" and the right-hand extreme equals 100 mm as "extreme fatigue". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high levels of fatigue).

    Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment

  22. Cortisone Intake AUC (Time- and Weight-Weighted)

    All cortisone intakes (in mg) were taken into account (oral, IV \[including the cortisone administration before the rituximab infusion\], intramuscular, and intra-articular).

    Time frame: Day 1 (each infusion), Week 24, Week 104

  23. Total Mean Dose of Cortisone Between Week 24 and Week 104

    All cortisone intakes were taken into account, including oral, IV (including the cortisone administration before the rituximab infusion), intramuscular and intra-articular.

    Time frame: Week 24 to Week 104

  24. HAQ-DI Scores

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.

    Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment

  25. Short Form 12 (SF-12) Physical Health Composite Score

    Physical and Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.

    Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment

  26. SF-12 Mental Health Composite Score

    Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.

    Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment

  27. Medical Outcomes Study Sleep Scale (MOS-Sleep) Composite Sleep Problems 6 (SLP6) Index

    The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The SLP6 index is comprised of 6 items: provides a summary of sleep problems and contains questions from the sleep disturbance, sleep adequacy, respiratory impairment, and somnolence domains. The SLP6 index score ranges between 0 and 100, with higher values corresponding to more sleep problems.

    Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment

  28. Percentage of Participants Reporting Acceptable Disease Activity Symptom State Assessed Using Patient Acceptable and Unacceptable Symptom State (PASS)

    Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of disease activity they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".

    Time frame: Week 24, 12 and 24 weeks after 1st retreatment

  29. Patient Global Assessment of Disease Activity in Participants Reporting Acceptable Symptoms Using PASS

    The Patient's Global Assessment of Disease Activity assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).

    Time frame: Week 24, 12 and 24 weeks after 1st retreatment

  30. Percentage of Participants With Minimum Clinically Important Improvement (MCII) in Disease Activity

    Participants were asked how their disease activity had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse-more disease activity.

    Time frame: Week 24, 12 and 24 weeks after 1st retreatment

  31. Change From Baseline in Patient Global Assessment of Disease Activity in Participants With MCII

    The Patient's Global Assessment of Disease Activity was assessed in participants reporting MCII on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).

    Time frame: Baseline, Week 24, 12 and 24 weeks after 1st retreatment

  32. Percentage of Participants Reporting Acceptable Symptom State in Functioning Assessed Using PASS

    Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of function they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of function they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".

    Time frame: Week 24, 12 and 24 weeks after 1st retreatment

  33. HAQ-DI Scores in Participants Reporting Acceptable Function Using PASS

    HAQ-DI was assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours). HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.

    Time frame: Week 24, 12 and 24 weeks after 1st retreatment

  34. Percentage of Participants With MCII in Functioning

    Participants were asked how their functioning had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse.

    Time frame: Week 24, 12 and 24 weeks after 1st retreatment

  35. Change From Baseline in HAQ-DI in Participants With MCII

    HAQ-DI was assessed in participants with MCII. HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.

    Time frame: Baseline, Week 24, 12 and 24 weeks after 1st retreatment

  36. Percentage of Participants With Acceptable Symptom State in Pain Assessed Using PASS

    Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of pain they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".

    Time frame: Week 24, 12 and 24 weeks after 1st retreatment

  37. Patient Global Assessment of Pain in Participants Reporting Acceptable Symptoms Using PASS

    Patient Global Assessment of Pain assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Higher values correspond to worst state of participant (high pain levels).

    Time frame: Week 24, 12 and 24 weeks after 1st retreatment

  38. Percentage of Participants With MCII in Pain

    Participants were asked how their pain had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse pain.

    Time frame: Week 24, 12 and 24 weeks after 1st retreatment

  39. Change From Baseline in Patient Global Assessment of Pain in Participants With MCII

    The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).

    Time frame: Baseline, Week 24, 12 and 24 weeks after 1st retreatment

07

Results

Posted Sep 15, 2014
Limitations and caveats
Nonserious adverse events (AEs) presented in this record include all AEs reported during the study, not just nonserious events.

Participant flow

Participant flow — Overall Study
MilestoneRandomized Retreatment Arm A: Rituximab 1000 Milligrams (mg)Randomized Retreatment Arm B: Rituximab 1000 mg x 2Nonrandomized: Rituximab 1000 mg
Started707381
Completed606155
Not completed101226
Withdrew: Adverse event024
Withdrew: Death010
Withdrew: Lack of efficacy6111
Withdrew: Lost to follow-up122
Withdrew: Withdrawal by subject256
Withdrew: Protocol violation001
Withdrew: Administrative reason or other112

Outcome measures

SecondaryDAS28-CRP During the Initial Treatment

Mean DAS28-CRP at Week 24 of the Initial Treatment study. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-CRP ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.

Time frame:
Days 1 and 15, and Weeks 6, 12, and 24
Reported as:
Mean · units on a scale
DAS28-CRP During the Initial Treatment
units on a scaleRandomized GroupNonrandomized Group
First Course, Day 15.82 ± 0.855.77 ± 0.90
First Course, Day 155.33 ± 1.095.42 ± 1.07
Follow-up, Week 64.69 ± 0.955.12 ± 1.05
Follow-up, Week 124.13 ± 0.915.00 ± 1.19
Follow-up, Week 243.65 ± 0.855.24 ± 1.08
SecondaryDAS28-CRP and Changes From Baseline to Week 24 in DAS28-CRP by Retreatment Course

DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.

Time frame:
Day 1, 24 weeks following each infusion up to 72 Weeks
Reported as:
Mean · units on a scale
DAS28-CRP and Changes From Baseline to Week 24 in DAS28-CRP by Retreatment Course
units on a scaleRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Initial treatment, Day 1 (n=70,73)5.79 ± 0.855.84 ± 0.86
Initial treatment, Week 24 (n=70,73)3.57 ± 0.893.73 ± 0.80
Change at Week 24 (n=70,73)-2.22 ± 0.96-2.11 ± 0.93
1st retreatment, Day 1 (n=66,68)4.33 ± 0.914.45 ± 0.80
1st retreatment, Week 24 (n=66,68)3.67 ± 1.153.69 ± 1.05
1st retreatment, Change at Week 24 (n=66,68)-0.67 ± 1.15-0.79 ± 1.13
2nd retreatment, Day 1 (n=49,48)4.60 ± 0.874.55 ± 0.96
2nd retreatment, Week 24 (n=41,39)3.72 ± 1.103.76 ± 1.12
2nd retreatment, Change at Week 24 (n=41,39)-0.94 ± 1.17-0.78 ± 1.07
Statistical analysis
  • Randomized Retreatment Arm A: Rituximab 1000 mg vs Randomized Retreatment Arm B: Rituximab 1000 mg x 2 · Wilcoxon (Mann-Whitney) · p = 0.465
  • Randomized Retreatment Arm A: Rituximab 1000 mg vs Randomized Retreatment Arm B: Rituximab 1000 mg x 2 · Wilcoxon (Mann-Whitney) · p = 0.161
  • Randomized Retreatment Arm A: Rituximab 1000 mg vs Randomized Retreatment Arm B: Rituximab 1000 mg x 2 · Student t-test · p = 0.524
PrimaryDisease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 104

DAS28-CRP was based on joint counts, overall participant assessment, and serum CRP levels (measured in milligrams per liter \[mg/L\]) at each visit. Joint counts included swollen joint count (SJC) and tender joint count (TJC). Total score range was 0 to 9.4; a higher score indicated more disease activity. DAS28-CRP less than or equal to (≤)3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and less than (\<)2.6 equals (=) remission. The AUC of all DAS28-CRP values between Day 1 and Week 104 (15 values of protocol visits) was calculated using the trapeze method (AUC between t1 and t2=(t2-t1)\*((DAS28-CRP at t1 + DAS28-CRP at t2)/2). The true visit dates were used to calculate the time between 2 DAS28-CRP evaluations. All the AUC were censored at Week 104 (linear extrapolation using the 2 last DAS28-CRP values (Weeks 96 and 104) to obtain the "true" DAS28-CRP value at the "true" Week 104).

Time frame:
Week 104
Reported as:
Mean · score on a scale*week
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 104
score on a scale*weekRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 1042761.4 ± 507.82666.0 ± 490.4
Statistical analysis
  • Randomized Retreatment Arm A: Rituximab 1000 mg vs Randomized Retreatment Arm B: Rituximab 1000 mg x 2 · Adjusted difference: 51.38 · 95% CI -131.22 to 233.98Covariate analysis with baseline DAS28-CRP value as covariate
SecondaryPercentage of Participants Achieving Clinical Remission (DAS28-CRP <2.6) or Low Disease Activity (DAS28-CRP ≤3.2)

Percentage of participants with clinical remission and low disease activity as measured by DAS28-CRP for Arm A and Arm B at Week 24 of the Initial Treatment, at 24 weeks after first re-treatment, and at 24 weeks after second retreatment. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity and \<2.6 = remission.

Time frame:
Week 24 of the Initial Treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission (DAS28-CRP <2.6) or Low Disease Activity (DAS28-CRP ≤3.2)
percentage of participantsRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Remission: Initial Treatment, Week 24 (n=70,73)14.38.2
Remission: 1st Re-treatment, Week 24 (n=66,67)18.29.0
Remission: 2nd Retreatment, Week 24 (n=43,40)16.37.5
Low activity: Initial Treatment, Week 24 (n=70,73)37.127.4
Low activity: 1st Retreatment, Week 24 (n=66,67)34.835.8
Low activity: 2nd Retreatment, Week 24 (n=43,40)27.930.0
SecondaryDAS28-CRP AUC Weighted Time

DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.

Time frame:
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Reported as:
Mean · units on a scale*week
DAS28-CRP AUC Weighted Time
units on a scale*weekRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
DAS28-CRP AUC Weighted Time3.82 ± 0.713.88 ± 0.71
SecondaryTime to Achieve DAS28-CRP Remission After the First Course

DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.

Time frame:
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Reported as:
Median · weeks
Time to Achieve DAS28-CRP Remission After the First Course
weeksRandomized Group
Time to Achieve DAS28-CRP Remission After the First Course56.0 (34.9 to NA)
SecondaryTime to Achieve DAS28-CRP Remission After Retreatment

DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.

Time frame:
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Reported as:
Median · weeks
Time to Achieve DAS28-CRP Remission After Retreatment
weeksRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
1st retreatment (n=66,68)NA (NA to NA)78.1 (37.0 to NA)
2nd retreatment (n=49,48)NA (NA to NA)NA (NA to NA)
SecondaryTime to Achieve DAS28-CRP ≤3.2 After the First Course of Treatment

DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.

Time frame:
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Reported as:
Median · weeks
Time to Achieve DAS28-CRP ≤3.2 After the First Course of Treatment
weeksRandomized Group
Time to Achieve DAS28-CRP ≤3.2 After the First Course of Treatment28.0 (25.4 to NA)
SecondaryTime to Achieve DAS28-CRP ≤3.2 After Retreatment

DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.

Time frame:
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Reported as:
Median · weeks
Time to Achieve DAS28-CRP ≤3.2 After Retreatment
weeksRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
1st retreatment (n=66,68)31.0 (21.1 to NA)22.1 (14.1 to 47.9)
2nd retreatment (n=49,48)16.9 (14.1 to 33.9)29.0 (15.0 to NA)
SecondaryDuration of DAS28-CRP Remission After the First Course of Treatment

DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.

Time frame:
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Reported as:
Median · weeks
Duration of DAS28-CRP Remission After the First Course of Treatment
weeksRandomized Group
Duration of DAS28-CRP Remission After the First Course of Treatment11.7 (8.0 to 15.1)
SecondaryDuration of DAS28-CRP Remission After Retreatment

DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.

Time frame:
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Reported as:
Median · weeks
Duration of DAS28-CRP Remission After Retreatment
weeksRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
1st retreatment (n=21,22)16.0 (15.0 to 17.0)8.0 (7.7 to 15.1)
2nd retreatment (n=17,11)9.0 (8.0 to 16.3)8.0 (8.0 to 16.0)
SecondaryDuration of DAS28-CRP ≤3.2 After the First Course of Treatment

DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.

Time frame:
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Reported as:
Median · weeks
Duration of DAS28-CRP ≤3.2 After the First Course of Treatment
weeksRandomized Group
Duration of DAS28-CRP ≤3.2 After the First Course of Treatment14.3 (9.0 to 18.6)
SecondaryDuration of DAS28-CRP ≤3.2 After Retreatment

DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.

Time frame:
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Reported as:
Median · weeks
Duration of DAS28-CRP ≤3.2 After Retreatment
weeksRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
1st retreatment (n=35,40)27.0 (22.7 to 32.0)17.0 (9.0 to 28.0)
2nd retreatment (n=29,23)10.1 (8.0 to 32.1)16.0 (9.0 to 31.1)
SecondaryPercentage of Participants Achieving American College of Rheumatology 20%, 50%, and 70% Improvement (ACR20/ACR50/ACR70)

ACR20/50/70 response defined as ≥20%, 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%, 50%, or 70% improvement, respectively, in at least 3 of 5 remaining ACR core measures: Patient Global Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity (on a visual analog scale \[VAS\]); Health Assessment Questionnaire-Disability Index (HAQ-DI); and CRP.

Time frame:
Week 24 of the initial treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20%, 50%, and 70% Improvement (ACR20/ACR50/ACR70)
percentage of participantsRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
ACR20: Initial Treatment, Week 2478.675.3
ACR20: 1st Retreatment, Week 2463.661.2
ACR20: 2nd Retreatment, Week 2465.160.0
ACR50: Initial Treatment, Week 2435.732.9
ACR50: 1st Retreatment, Week 2433.332.8
ACR50: 2nd Retreatment, Week 2432.642.5
ACR70: Initial Treatment, Week 2412.911.0
ACR70: 1st Retreatment, Week 2416.719.4
ACR70: 2nd Retreatment, Week 2418.620.0
SecondaryPercentage of Participants Achieving a Response During Initial Treatment by European League Against Rheumatism (EULAR) Category

DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline \>1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤ 5.1 or change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline \>0.6 and ≤ 1.2 with a DAS28 score of \>5.1.

Time frame:
Day 15, Weeks 6, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response During Initial Treatment by European League Against Rheumatism (EULAR) Category
percentage of participantsRandomized GroupNonrandomized Group
Good response: Day 1543
Good response: Week 654
Good response: Week 12154
Good response: Week 24323
Moderate response: Day 152220
Moderate response: Week 65929
Moderate response: Week 127335
Moderate response: Week 246615
No response: Day 157478
No response: Week 63667
No response: Week 121161
No response: Week 24382
SecondaryPercentage of Participants Achieving a Response During Retreatment by EULAR Category

DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline \>1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤ 5.1 or change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline \>0.6 and ≤ 1.2 with a DAS28 score of \>5.1.

Time frame:
Week 24, 24 weeks after 1st retreatment, 24 weeks after 2nd retreatment
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response During Retreatment by EULAR Category
percentage of participantsRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Good response: Week 24 (n=70,73)3726
Good response: 1st retreatment (n=66,67)3536
Good response: 2nd retreatment (n=43,40)2830
Moderate response: Week 24 (n=70,73)6071
Moderate response: 1st retreatment (n=66,67)5352
Moderate response: 2nd retreatment (n=43,40)5450
No response: Week 24 (n=70,73)33
No response: 1st retreatment (n=66,67)1212
No response: 2nd retreatment (n=43,40)1920
SecondaryPercentage of Participants With Rheumatoid Factor (RF) at 24 Weeks After Treatment

RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 international units per milliliter (IU/mL) is considered positive.

Time frame:
Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment
Reported as:
Number · percentage of participants
Percentage of Participants With Rheumatoid Factor (RF) at 24 Weeks After Treatment
percentage of participantsRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Negative: Initial treatment, Week 24 (n=69,71)33.3 ± 273.0938.0 ± 408.24
Positive: Initial treatment, Week 24 (n=69,71)66.7 ± 114.6362.0 ± 386.02
Negative: 1st Retreatment, Week 24 (n=44,43)36.4 ± 79.1448.8 ± 65.29
Positive: 1st Retreatment, Week 24 (n=44,43)63.6 ± 75.6851.2 ± 41.01
Negative: 2nd retreatment, Week 24 (n=15,12)46.783.3
Positive: 2nd retreatment, Week 24 (n=15,12)53.316.7
SecondaryPercentage of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at 24 Weeks After Treatment

Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual's own proteins) that are frequently detected in the blood of rheumatoid arthritis participants. Anti-CCP antibodies value higher than 10 U/mL is considered positive.

Time frame:
Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at 24 Weeks After Treatment
percentage of participantsRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Negative: Initial treatment, Week 24 (n=69,71)17.422.5
Positive: Initial treatment, Week 24 (n=69,71)82.677.5
Negative: 1st Retreatment, Week 24 (n=44,43)22.720.9
Positive: 1st Retreatment, Week 24 (n=44,43)77.379.1
Negative: 2nd retreatment, Week 24 (n=15,12)13.341.7
Positive: 2nd retreatment, Week 24 (n=15,12)86.758.3
SecondaryPhysician's Global Assessment of Disease Activity

The Physician's Global Assessment of disease activity is assessed on a 0 to 100 millimeter (mm) horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Physicians were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high disease activity).

Time frame:
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Reported as:
Mean · mm
Physician's Global Assessment of Disease Activity
mmRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Initial treatment, Day 1 (n=70,73)65.0 ± 15.064.1 ± 15.0
Initial treatment, Week 24 (n=69,71)27.9 ± 18.627.2 ± 16.2
Before 1st retreatment (n=64,63)33.7 ± 17.426.9 ± 17.1
1st retreatment, Day 1 (n=60,61)44.4 ± 20.843.3 ± 18.5
1st retreatment, Week 12 (n=56,62)30.4 ± 18.828.4 ± 18.0
1st retreatment, Week 24 (n=60,59)31.9 ± 19.124.8 ± 16.3
SecondaryPatient Global Assessment of Disease Activity

The Patient's Global Assessment of Disease Activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).

Time frame:
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Reported as:
Mean · mm
Patient Global Assessment of Disease Activity
mmRandomized Re-treatment Arm A: Single 1000 mg IV RituximabRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Initial treatment, Day 1 (n=70,73)63.0 ± 20.464.2 ± 18.0
Initial treatment, Week 24 (n=70,73)29.9 ± 22.332.6 ± 22.7
Before 1st retreatment (n=65,67)33.2 ± 19.634.7 ± 22.3
1st retreatment, Day 1 (n=65,66)43.7 ± 21.246.6 ± 21.3
1st retreatment, Week 12 (n=63,65)34.8 ± 21.234.5 ± 25.3
1st retreatment, Week 24 (n=64,60)35.1 ± 24.634.1 ± 23.1
SecondaryPatient's Global Assessment of Pain

The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).

Time frame:
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Reported as:
Mean · mm
Patient's Global Assessment of Pain
mmRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Initial Treatment, Day 1 (n=70,73)61.9 ± 22.360.1 ± 19.9
Initial Treatment, Week 24 (n=70,73)28.5 ± 22.030.0 ± 21.7
Before 1st retreatment (n=65,67)34.4 ± 21.332.9 ± 23.0
1st re-treatment, Day 1 (n=65,67)41.1 ± 21.545.2 ± 22.4
1st retreatment, Week 12 (n=64,60)34.3 ± 21.433.9 ± 25.6
1st retreatment, Week 24 (n=64,60)34.4 ± 24.634.3 ± 23.7
SecondaryParticipant Assessment of Fatigue

Participants were asked to rate their level of fatigue over the last 7 days on a 100-mm VAS. The left-hand extreme of the line equals 0 mm, and is described as "no fatigue" and the right-hand extreme equals 100 mm as "extreme fatigue". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high levels of fatigue).

Time frame:
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Reported as:
Mean · mm
Participant Assessment of Fatigue
mmRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Initial Treatment, Day 1 (n=70,73)62.1 ± 21.462.0 ± 22.5
Initial Treatment, Week 24 (n=70,73)37.1 ± 24.239.8 ± 25.8
Before 1st retreatment (n=64,66)44.5 ± 20.841.2 ± 26.1
1st retreatment, Day 1 (n=65,64)50.6 ± 22.651.7 ± 21.6
1st retreatment, Week 12 (n=63,65)45.2 ± 23.045.3 ± 25.5
1st retreatment, Week 24 (n=64,60)43.0 ± 25.338.9 ± 23.6
SecondaryCortisone Intake AUC (Time- and Weight-Weighted)

All cortisone intakes (in mg) were taken into account (oral, IV \[including the cortisone administration before the rituximab infusion\], intramuscular, and intra-articular).

Time frame:
Day 1 (each infusion), Week 24, Week 104
Reported as:
Mean · mg*week
Cortisone Intake AUC (Time- and Weight-Weighted)
mg*weekRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Day 1 to Week 104 (n=69,73)0.08 ± 0.060.09 ± 0.06
1st retreatment to Week 104 (n=65,68)0.08 ± 0.060.09 ± 0.06
Week 24 to Week 104 (n=69,73)0.08 ± 0.060.09 ± 0.06
Statistical analysis
  • Randomized Retreatment Arm A: Rituximab 1000 mg vs Randomized Retreatment Arm B: Rituximab 1000 mg x 2 · Wilcoxon (Mann-Whitney) · p = 0.389
  • Randomized Retreatment Arm A: Rituximab 1000 mg vs Randomized Retreatment Arm B: Rituximab 1000 mg x 2 · Wilcoxon (Mann-Whitney) · p = 0.374
  • Randomized Retreatment Arm A: Rituximab 1000 mg vs Randomized Retreatment Arm B: Rituximab 1000 mg x 2 · Wilcoxon (Mann-Whitney) · p = 0.277
SecondaryTotal Mean Dose of Cortisone Between Week 24 and Week 104

All cortisone intakes were taken into account, including oral, IV (including the cortisone administration before the rituximab infusion), intramuscular and intra-articular.

Time frame:
Week 24 to Week 104
Reported as:
Mean · mg
Total Mean Dose of Cortisone Between Week 24 and Week 104
mgRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Total cortisone: Week 24 to Week 1042542.9 ± 2085.62842.5 ± 2124.9
Oral cortisone: Week 24 to Week 1042384.0 ± 2092.62425.1 ± 2046.6
IV cortisone: Week 24 to Week 104199.1 ± 92.3384.9 ± 193.5
Statistical analysis
  • Randomized Retreatment Arm A: Rituximab 1000 mg vs Randomized Retreatment Arm B: Rituximab 1000 mg x 2 · Wilcoxon (Mann-Whitney) · p = 0.278
  • Randomized Retreatment Arm A: Rituximab 1000 mg vs Randomized Retreatment Arm B: Rituximab 1000 mg x 2 · Wilcoxon (Mann-Whitney) · p = 0.887
  • Randomized Retreatment Arm A: Rituximab 1000 mg vs Randomized Retreatment Arm B: Rituximab 1000 mg x 2 · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryHAQ-DI Scores

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.

Time frame:
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Reported as:
Mean · units on a scale
HAQ-DI Scores
units on a scaleRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Initial treatment, Day 1 (n=70,69)1.74 ± 0.611.75 ± 0.69
Initial treatment, Week 24 (n=68,72)1.25 ± 0.671.31 ± 0.74
Before 1st retreatment (n=64,67)1.26 ± 0.671.35 ± 0.73
1st retreatment, Day 1 (n=58,58)1.32 ± 0.681.42 ± 0.73
1st retreatment, Week 12 (n=62,61)1.31 ± 0.661.33 ± 0.72
1st retreatment, Week 24 (n=63,59)1.26 ± 0.721.32 ± 0.72
SecondaryShort Form 12 (SF-12) Physical Health Composite Score

Physical and Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.

Time frame:
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Reported as:
Mean · units on a scale
Short Form 12 (SF-12) Physical Health Composite Score
units on a scaleRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Initial treatment, Day 1 (n=62,65)31.11 ± 7.5531.07 ± 7.41
Initial Tteatment, Week 24 (n=63,68)38.81 ± 8.3940.05 ± 8.64
Before 1st retreatment (n=21,22)39.44 ± 8.4539.52 ± 9.99
1st retreatment, Day 1 (n=47,44)36.57 ± 6.7535.81 ± 8.97
1st retreatment, Week 12 (n=13,10)38.36 ± 9.3038.05 ± 10.77
1st retreatment, Week 24 (n=40,36)36.53 ± 7.7536.86 ± 8.13
SecondarySF-12 Mental Health Composite Score

Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.

Time frame:
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Reported as:
Mean · units on a scale
SF-12 Mental Health Composite Score
units on a scaleRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Initial treatment, Day 1 (n=62,65)36.03 ± 10.0337.13 ± 9.40
Initial treatment, Week 24 (n=63,68)43.08 ± 9.7440.99 ± 9.01
Before 1st retreatment (n=21,22)44.94 ± 9.9441.57 ± 8.66
1st retreatment, Day 1 (n=47,44)40.87 ± 10.5338.52 ± 7.87
1st retreatment, Week 12 (n=13,10)41.84 ± 11.3634.69 ± 11.06
1st retreatment, Week 24 (n=40,36)40.90 ± 10.6141.60 ± 8.87
SecondaryMedical Outcomes Study Sleep Scale (MOS-Sleep) Composite Sleep Problems 6 (SLP6) Index

The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The SLP6 index is comprised of 6 items: provides a summary of sleep problems and contains questions from the sleep disturbance, sleep adequacy, respiratory impairment, and somnolence domains. The SLP6 index score ranges between 0 and 100, with higher values corresponding to more sleep problems.

Time frame:
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Reported as:
Mean · units on a scale
Medical Outcomes Study Sleep Scale (MOS-Sleep) Composite Sleep Problems 6 (SLP6) Index
units on a scaleRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Initial treatment, Day 1 (n=68,66)52.15 ± 15.3249.89 ± 15.81
Initial treatment, Week 24 (n=65,70)43.73 ± 14.9040.50 ± 17.17
Before 1st retreatment (n=62,65)45.44 ± 13.9741.27 ± 17.01
1st retreatment, Day 1 (n=57,56)46.25 ± 16.5344.94 ± 16.02
1st retreatment, Week 12 (n=61,59)43.64 ± 14.4143.74 ± 18.60
1st retreatment, Week 24 (n=63,59)44.74 ± 15.3540.08 ± 16.76
SecondaryPercentage of Participants Reporting Acceptable Disease Activity Symptom State Assessed Using Patient Acceptable and Unacceptable Symptom State (PASS)

Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of disease activity they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".

Time frame:
Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Acceptable Disease Activity Symptom State Assessed Using Patient Acceptable and Unacceptable Symptom State (PASS)
percentage of participantsRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 2473.475.4
1st retreatment, Week 1273.362.5
1st retreatment, Week 2470.564.3
SecondaryPatient Global Assessment of Disease Activity in Participants Reporting Acceptable Symptoms Using PASS

The Patient's Global Assessment of Disease Activity assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).

Time frame:
Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Mean · mm
Patient Global Assessment of Disease Activity in Participants Reporting Acceptable Symptoms Using PASS
mmRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 24 (n=47,52)23.4 ± 18.528.4 ± 19.1
1st retreatment, Week 12 (n=44,35)27.4 ± 16.627.3 ± 21.8
1st retreatment, Week 24 (n=43,36)26.3 ± 19.525.7 ± 16.4
SecondaryPercentage of Participants With Minimum Clinically Important Improvement (MCII) in Disease Activity

Participants were asked how their disease activity had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse-more disease activity.

Time frame:
Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Number · percentage of participants
Percentage of Participants With Minimum Clinically Important Improvement (MCII) in Disease Activity
percentage of participantsRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 2475.481.2
1st retreatment, Week 1265.663.0
1st retreatment, Week 2466.766.1
SecondaryChange From Baseline in Patient Global Assessment of Disease Activity in Participants With MCII

The Patient's Global Assessment of Disease Activity was assessed in participants reporting MCII on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).

Time frame:
Baseline, Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of Disease Activity in Participants With MCII
mmRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 24 (n=49,56)-12.4 ± 20.7-4.6 ± 22.9
1st retreatment, Week 12 (n=38,30)-4.2 ± 16.0-9.2 ± 17.7
1st retreatment, Week 24 (n=40,37)-2.5 ± 17.8-2.9 ± 20.6
SecondaryPercentage of Participants Reporting Acceptable Symptom State in Functioning Assessed Using PASS

Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of function they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of function they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".

Time frame:
Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Acceptable Symptom State in Functioning Assessed Using PASS
percentage of participantsRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 2474.272.7
1st retreatment, Week 1275.960.0
1st retreatment, Week 2470.262.1
SecondaryHAQ-DI Scores in Participants Reporting Acceptable Function Using PASS

HAQ-DI was assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours). HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.

Time frame:
Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Mean · units on a scale
HAQ-DI Scores in Participants Reporting Acceptable Function Using PASS
units on a scaleRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 24 (n=46,48)1.16 ± 0.691.16 ± 0.74
1st retreatment, Week 12 (n=44,33)1.20 ± 0.701.08 ± 0.71
1st retreatment, Week 24 (n=40,36)1.14 ± 0.751.08 ± 0.72
SecondaryPercentage of Participants With MCII in Functioning

Participants were asked how their functioning had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse.

Time frame:
Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Number · percentage of participants
Percentage of Participants With MCII in Functioning
percentage of participantsRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 2473.476.5
1st retreatment, Week 1265.063.0
1st retreatment, Week 2465.557.9
SecondaryChange From Baseline in HAQ-DI in Participants With MCII

HAQ-DI was assessed in participants with MCII. HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.

Time frame:
Baseline, Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Mean · units on a scale
Change From Baseline in HAQ-DI in Participants With MCII
units on a scaleRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 24 (n=47,52)-0.11 ± 0.46-0.06 ± 0.56
1st retreatment, Week 12 (n=38,30)-0.03 ± 0.30-0.11 ± 0.39
1st retreatment, Week 24 (n=38,30)-0.07 ± 0.24-0.09 ± 0.29
SecondaryPercentage of Participants With Acceptable Symptom State in Pain Assessed Using PASS

Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of pain they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".

Time frame:
Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Number · percentage of participants
Percentage of Participants With Acceptable Symptom State in Pain Assessed Using PASS
percentage of participantsRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 2474.275.0
1st retreatment Week 1270.261.8
1st retreatment, Week 2472.961.4
SecondaryPatient Global Assessment of Pain in Participants Reporting Acceptable Symptoms Using PASS

Patient Global Assessment of Pain assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Higher values correspond to worst state of participant (high pain levels).

Time frame:
Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Mean · mm
Patient Global Assessment of Pain in Participants Reporting Acceptable Symptoms Using PASS
mmRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 24 (n=46,51)21.5 ± 16.226.4 ± 18.5
1st retreatment, Week 12 (n=40,34)26.8 ± 17.327.6 ± 22.4
1st retreatment, Week 24 (n=43,35)26.3 ± 20.125.1 ± 17.3
SecondaryPercentage of Participants With MCII in Pain

Participants were asked how their pain had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse pain.

Time frame:
Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Number · percentage of participants
Percentage of Participants With MCII in Pain
percentage of participantsRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 24 (n=63,70)76.280.0
1st retreatment, Week 12 (n=59,55)71.269.1
1st retreatment, Week 24 (n=61,57)68.961.4
SecondaryChange From Baseline in Patient Global Assessment of Pain in Participants With MCII

The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).

Time frame:
Baseline, Week 24, 12 and 24 weeks after 1st retreatment
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of Pain in Participants With MCII
mmRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2
Week 24 (n=48,56)-13.5 ± 21.0-4.3 ± 23.9
1st retreatment, Week 12 (n=39,35)-2.7 ± 13.6-8.9 ± 16.4
1st retreatment, Week 24 (n=42,35)-3.5 ± 24.3-3.2 ± 18.4

Adverse events

Collected over Baseline to 104 weeks; related serious adverse events (SAEs) were collected and reported regardless of time elapsed from last dose of study drug; unrelated SAEs were collected during the study and for up to 24 weeks after last dose of study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Retreatment Arm A: Rituximab 1000 mg—19/66 (28.8%)61/66 (92.4%)
Randomized Retreatment Arm B: Rituximab 1000 mg x 2—25/68 (36.8%)65/68 (95.6%)
Nonrandomized: Rituximab 1000 mg—16/81 (19.8%)72/81 (88.9%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2Nonrandomized: Rituximab 1000 mg
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/664/682/81
OsteoarthritisMusculoskeletal and connective tissue disorders2/662/681/81
ArthralgiaMusculoskeletal and connective tissue disorders1/662/681/81
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/660/682/81
ArthropathyMusculoskeletal and connective tissue disorders1/661/680/81
ArthritisMusculoskeletal and connective tissue disorders1/660/680/81
Rheumatoid noduleMusculoskeletal and connective tissue disorders1/660/680/81
Abdominal wall abscessInfections and infestations1/660/680/81
Bursitis infectiveInfections and infestations1/660/680/81
CellulitisInfections and infestations1/660/680/81
Most frequent other events
Showing 10 of 325
Most frequent other events
EventRandomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2Nonrandomized: Rituximab 1000 mg
BronchitisInfections and infestations13/6616/6811/81
Urinary tract infectionInfections and infestations9/6612/6814/81
Rheumatoid arthritisMusculoskeletal and connective tissue disorders8/6612/688/81
AstheniaGeneral disorders11/6611/686/81
CoughRespiratory, thoracic and mediastinal disorders11/664/683/81
HeadacheNervous system disorders7/6611/6810/81
Back painMusculoskeletal and connective tissue disorders10/6610/683/81
GastroenteritisInfections and infestations8/6610/683/81
NasopharyngitisInfections and infestations7/666/682/81
NauseaGastrointestinal disorders7/665/686/81

Baseline characteristics

Age, Continuous
Age, Continuous(years)Randomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2Nonrandomized: Rituximab 1000 mgTotal
Mean54.5 ± 11.557.2 ± 10.456.1 ± 11.256.0 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Randomized Retreatment Arm A: Rituximab 1000 mgRandomized Retreatment Arm B: Rituximab 1000 mg x 2Nonrandomized: Rituximab 1000 mgTotal
Female556270187
Male15111137
08

Study locations

53 sites
  • Abbeville, 80142, France
  • Agen, 47923, France
  • Aix En Provence, 13616, France
  • Aix Les Bains, 73106, France
  • Amiens, 80054, France
  • Belfort, 90016, France
  • Berck, 62600, France
  • Bobigny, 93009, France
  • Bois-guillaume, 76233, France
  • Boulogne-billancourt, 92104, France
  • Brest, 29609, France
  • Caen, 14033, France
  • Cahors, 46005, France
  • Clermont-ferrand, 63003, France
  • Corbeil-essonnes, 91106, France
  • Echirolles, 38434, France
  • La Roche Sur Yon, 85925, France
  • Le Kremlin Bicetre, 94275, France
  • Libourne, 33505, France
  • Lievin, 62800, France
  • Lille, 59037, France
  • Limoges, 87042, France
  • Lomme, 59462, France
  • Lyon, 69365, France
  • Marseille, 13013, France
  • Montivilliers, 76290, France
  • Montpellier, 34295, France
  • Nantes, 44035, France
  • Narbonne, 11108, France
  • Nice, 06202, France
  • Paris, 75019, France
  • Paris, 75475, France
  • Paris, 75571, France
  • Paris, 75651, France
  • Paris, 75674, France
  • Paris, 75679, France
  • Paris, 75877, France
  • PAU, 64046, France
  • Perpignan, 66046, France
  • Pessac, 33600, France
  • Pierre Benite, 69495, France
  • Poitiers, 86021, France
  • Reims, 51100, France
  • Rennes, 35203, France
  • Saint-etienne, 4200, France
  • Strasbourg, 67098, France
  • Toulon, 83100, France
  • Toulouse, 31054, France
  • Toulouse, 31059, France
  • Valence, 26000, France
  • Valenciennes, 59322, France
  • Vandoeuvre-les-nancy, 54511, France
  • Vannes, 56017, France
09

References and documents

Publications

  • de Jong TD, Sellam J, Agca R, Vosslamber S, Witte BI, Tsang-A-Sjoe M, Mantel E, Bijlsma JW, Voskuyl AE, Nurmohamed MT, Verweij CL, Mariette X. A multi-parameter response prediction model for rituximab in rheumatoid arthritis. Joint Bone Spine. 2018 Mar;85(2):219-226. doi: 10.1016/j.jbspin.2017.02.015. Epub 2017 Mar 28. PubMed 28363827 ↗
  • Sellam J, Riviere E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferraccioli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2016 Dec 13;18(1):294. doi: 10.1186/s13075-016-1190-z. Erratum In: Arthritis Res Ther. 2017 Jan 23;19(1):11. doi: 10.1186/s13075-017-1221-4. PubMed 27964756 ↗
  • Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, Le Loet X, Tebib J, Jourdan R, Dougados M, Taoufik Y, Mariette X. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2013 Sep;65(9):2253-61. doi: 10.1002/art.38023. PubMed 23740460 ↗
  • Mariette X, Rouanet S, Sibilia J, Combe B, Le Loet X, Tebib J, Jourdan R, Dougados M. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014 Aug;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480. Epub 2013 May 30. PubMed 23723317 ↗
  • Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loet X, Combe B, Dougados M, Mariette X, Taoufik Y. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2011 Dec;63(12):3692-701. doi: 10.1002/art.30599. PubMed 22127692 ↗
  • Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loet X, Tebib J, Sibilia J, Taoufik Y, Dougados M, Mariette X. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011 Apr;63(4):933-8. doi: 10.1002/art.30233. PubMed 21225699 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2010
First posted
May 19, 2010
Start
Sep 2006
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Sep 15, 2014
Last update
Sep 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01126541
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 19, 2010
Start date
Sep 2006
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Sep 15, 2014
Last update
Sep 15, 2014

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion